Cargando…

Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK

The proportion of SARS-CoV-2 infections ascertained through healthcare and community testing is generally unknown and expected to vary depending on natural factors and changes in test-seeking behaviour. Here we use population surveillance data and reported daily case numbers in the United Kingdom to...

Descripción completa

Detalles Bibliográficos
Autores principales: Colman, Ewan, Puspitarani, Gavrila A., Enright, Jessica, Kao, Rowland R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636607/
https://www.ncbi.nlm.nih.gov/pubmed/36347306
http://dx.doi.org/10.1016/j.jtbi.2022.111333
_version_ 1784824982437625856
author Colman, Ewan
Puspitarani, Gavrila A.
Enright, Jessica
Kao, Rowland R.
author_facet Colman, Ewan
Puspitarani, Gavrila A.
Enright, Jessica
Kao, Rowland R.
author_sort Colman, Ewan
collection PubMed
description The proportion of SARS-CoV-2 infections ascertained through healthcare and community testing is generally unknown and expected to vary depending on natural factors and changes in test-seeking behaviour. Here we use population surveillance data and reported daily case numbers in the United Kingdom to estimate the rate of case ascertainment. We mathematically describe the relationship between the ascertainment rate, the daily number of reported cases, population prevalence, and the sensitivity of PCR and Lateral Flow tests as a function time since exposure. Applying this model to the data, we estimate that 20%–40% of SARS-CoV-2 infections in the UK were ascertained with a positive test with results varying by time and region. Cases of the Alpha variant were ascertained at a higher rate than the wild type variants circulating in the early pandemic, and higher again for the Delta variant and Omicron BA.1 sub-lineage, but lower for the BA.2 sub-lineage. Case ascertainment was higher in adults than in children. We further estimate the daily number of infections and compare this to mortality data to estimate that the infection fatality rate increased by a factor of 3 during the period dominated by the Alpha variant, and declined in line with the distribution of vaccines. This manuscript was submitted as part of a theme issue on “Modelling COVID-19 and Preparedness for Future Pandemics”.
format Online
Article
Text
id pubmed-9636607
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-96366072022-11-07 Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK Colman, Ewan Puspitarani, Gavrila A. Enright, Jessica Kao, Rowland R. J Theor Biol Article The proportion of SARS-CoV-2 infections ascertained through healthcare and community testing is generally unknown and expected to vary depending on natural factors and changes in test-seeking behaviour. Here we use population surveillance data and reported daily case numbers in the United Kingdom to estimate the rate of case ascertainment. We mathematically describe the relationship between the ascertainment rate, the daily number of reported cases, population prevalence, and the sensitivity of PCR and Lateral Flow tests as a function time since exposure. Applying this model to the data, we estimate that 20%–40% of SARS-CoV-2 infections in the UK were ascertained with a positive test with results varying by time and region. Cases of the Alpha variant were ascertained at a higher rate than the wild type variants circulating in the early pandemic, and higher again for the Delta variant and Omicron BA.1 sub-lineage, but lower for the BA.2 sub-lineage. Case ascertainment was higher in adults than in children. We further estimate the daily number of infections and compare this to mortality data to estimate that the infection fatality rate increased by a factor of 3 during the period dominated by the Alpha variant, and declined in line with the distribution of vaccines. This manuscript was submitted as part of a theme issue on “Modelling COVID-19 and Preparedness for Future Pandemics”. The Author(s). Published by Elsevier Ltd. 2023-02-07 2022-11-05 /pmc/articles/PMC9636607/ /pubmed/36347306 http://dx.doi.org/10.1016/j.jtbi.2022.111333 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Colman, Ewan
Puspitarani, Gavrila A.
Enright, Jessica
Kao, Rowland R.
Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK
title Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK
title_full Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK
title_fullStr Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK
title_full_unstemmed Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK
title_short Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK
title_sort ascertainment rate of sars-cov-2 infections from healthcare and community testing in the uk
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636607/
https://www.ncbi.nlm.nih.gov/pubmed/36347306
http://dx.doi.org/10.1016/j.jtbi.2022.111333
work_keys_str_mv AT colmanewan ascertainmentrateofsarscov2infectionsfromhealthcareandcommunitytestingintheuk
AT puspitaranigavrilaa ascertainmentrateofsarscov2infectionsfromhealthcareandcommunitytestingintheuk
AT enrightjessica ascertainmentrateofsarscov2infectionsfromhealthcareandcommunitytestingintheuk
AT kaorowlandr ascertainmentrateofsarscov2infectionsfromhealthcareandcommunitytestingintheuk